Semaglutide faces renewed legal battles as Novo Nordisk targets compounding pharmacies for trademark infringement and false advertising after FDA shortage removal.
Dani Heba
Advertisement
Dani Heba is a summer associate in Hunton’s New York office.
Articles by Dani Heba
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Medical Economics
1
What medical practices need to know about the private equity resurgence
2
Improved physician leadership: A key to better health care
3
Investing in the nuclear power renaissance
4
FDA clears neonatal MRI system designed for NICU use
5